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Introduction
Recent advances in technology have made obtainable a 
range of point-of-care devices that can perform clinical 
analyses to anaesthesiologists which until recently, were 
only available from laboratories. Increasingly rapid access 
to some of these tests may well change anaesthetic 
practice, but the benefits, pitfalls and limitations of point-of-
care devices must be appreciated.
Glucometers 
Hypoglycaemia kills neurones, and hyperglycaemia 
aggravates inflammatory damage and impairs 
wound healing and immunity. Both must be avoided 
intraoperatively. A laboratory assay of plasma glucose 
concentration is accurate, but is impractically slow in an 
emergency. Glucometers measure whole blood glucose 
concentration within minutes, but with potential for errors 
that may influence patient safety. While measuring whole 
blood glucose concentration, glucometers make allowance 
for expected erythrocyte mass and display plasma glucose 
concentration equivalents to allow comparability with a 
laboratory assay, but the presence of hypertriglyceridaemia 
or paraproteinaemia will confound this, and glucometers 
will reflect pseudohypoglycaemia. 
Extremes of haematocrit may also affect readings. 
Glucometers that use the more specific glucose oxidase 
enzymatic technique are affected by blood oxygen tension 
(hyperoxia causes underestimation of whole blood glucose 
concentration and hypoxia leads to an overestimation), 
and those using the glucose 1-dehydrogenase technique 
falsely interpret non-glucose sugars, such as icodextrin, 
as glucose. Therapeutic paracetomol levels cause falsely 
high and low whole blood glucose concentration measures 
in glucose oxidase and glucose 1-dehydrogenase 
glucometers, respectively. Catecholamine infusions can 
also lead to major errors in point-of-care device glucose 
readings. Most worryingly, all glucometers, even if well 
calibrated in the euglycaemic range, are significantly 
more prone to error in hypoglycaemic patients. Most 
devices tend to read falsely high, which may mean that 
hypoglycaemia is missed. For this reason, while 3.5 mmol/l 
is the conventional “alert line” for treating hypoglycaemia 
with a laboratory assay, some authorities recommend a 
value of 3.9 mmol/l with glucometer readings. There are 
major variances in accuracy between devices, and users 
are advised to access independent published comparative 
analyses before purchasing glucometers for critical use. 
This is exceptionally important in paediatric and neonatal 
critical care. Very few of the available glucometers are 
precise enough for safe use in these populations, and 
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Point-of-care devices offer an increasing number of analytical tests more quickly than laboratory analysis, but clinicians must 
be aware of the limitations of these devices, especially for critical threshold-level decisions. Glucometers are susceptible 
to a wide range of errors, and only a few haemoglobin-measuring devices have accuracy approaching that of laboratory 
analysis. Activated coagulation time remains a useful but error-prone test for heparin effects. Thromboelastography and 
thromboelastometry offer insight into coagulation defects superior to conventional assays. Multi-function testers provide 
cardiac enzyme and lactate analysis that is becoming vital for intraoperative decision-making.
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expert group recommendations should be sought before 
purchases are made. Lastly, there is a predictable decrease 
in glucose concentration in simultaneously sampled arterial 
(highest), capillary and venous (lowest) blood. The blood 
sampling site must be standardised if comparisons are to 
be valid.1
Haemoglobinometers
A laboratory assay uses techniques such as 
cyanohaemoglobin measurement in lysed blood to most 
accurately quantify total haemoglobin concentration, but 
this requires complex equipment. Spun capillary tube 
haematocrit measurement and simple light-absorption 
devices have been used for years at the bedside, but 
these are no more than rough indications. Blood gas 
analysers which quantify haemoglobin concentration via 
spectrophotometry of intact blood are only slightly more 
precise. The HemoCue® Hb201 (HemoCue AB, Ängelholm, 
Sweden) uses cuvettes containing chemicals which lyse 
blood and generate measurable azidemethaemoglobin, 
a similar concept to formal laboratory assay tests. The 
HemoCue® system is now widely used, has shown 
reasonable and reliable concordance with laboratory assays 
in various studies. The HemoCue® HC is typically within 
1 g/dl of the laboratory assay haemoglobin concentration 
when arterial blood is used. Unsurprisingly, there are worse 
limits of agreement when capillary blood is used because 
of the greater possibility of sampling error. The clinician 
should be aware of these limits of agreement when patient 
haemoglobin concentration is close to a transfusion trigger.2 
Activated coagulation time 
Monitoring of therapeutic heparin effect is critical during 
any form of extracorporeal circulation using heparin 
anticoagulation. The laboratory assay-activated partial 
thromboplastin time (aPTT) is slow and has a nonlinear 
response relationship. The activated coagulation time, 
essentially a development of whole blood clotting time, 
shows a positive linear correlation with the heparin level. 
Clot initiation is via negatively charged molecules included 
in the assay tube, selected according to the expected 
heparin level, e.g. glass beads for a moderate heparin level, 
celite for a high heparin level and kaolin for a high heparin 
level with aprotinin, with specific target value ranges 
for each activator. The various manufacturers’ devices 
differ in methodological detail and also in their target 
ranges.3 Multiple preanalytical issues can affect activated 
coagulation time, hence samples must be carefully handled 
and clinicians should have a low threshold to repeat tests 
that yield unexpected results.
Thromboelastography and 
thromboelastometry
Bleeding diatheses commonly develop during emergency 
surgery, and can arise for many reasons, including hypo-
thermia, platelet insufficiency or dysfunction, deficiency 
of one or more coagulation factors and premature throm-
bolysis. Conventional laboratory assays are frequently 
inadequate in directing therapy. They take too long and are 
non-specific. (The international normalised ratio is designed 
to measure the effects of warfarin, and aPTT to measure the 
effects of heparin).
Thromboelastography and thromboelastometry are 
related, but separately developed point-of-care device 
technologies that are superior to a laboratory assay for 
the purposes of directing haemostasis management. The 
TEG® (Haemoscope Corp, Braintree, USA) and ROTEM® 
(Pentapharm GmbH, München, Germany) use these 
respective techniques to analyse the dynamics of clot 
formation in real time by assessing the shear elasticity of 
clotting blood. Each device has specific advantages and 
some proprietary tests, but both will provide information 
within 5-20 minutes which will facilitate the identification 
of the presence of a platelet disorder, deficiency of 
clotting factors (especially fibrinogen), the presence 
of anticoagulants, and within 45 minutes, evidence of 
hyperfibrinolysis, thus allowing targeted therapy that is 
more efficient, has fewer side-effects and costs less than 
broad-spectrum “shotgun” blood product administration. 
Performing the analyses requires more attention than the 
typical point-of-care device, and so someone other than the 
patient’s primary anaesthesiologist should probably run the 
test, but learning the technique of running the tests is within 
the capabilities of clinical staff in most theatre suites.4,5
Blood gas analysers
The archetypal point-of-care device, blood gas analysers, 
have increased in convenience because of the development 
of cartridge technology that minimises the need for daily 
technologist maintenance, have improved in accuracy 
as multifrequency spectrophotometry has been added 
to conventional electrodes, and have acquired additional 
testing modalities, such as glucose and electrolyte 
measurement. Blood gas analysis per se is beyond the scope 
of this article, but the utility of the additional technologies is 
important. Blood gas analyser-based K+ analysis is usually 
accurate enough for clinical decision-making and ionised 
calcium (Ca2+), which is far more immediately useful than 
laboratory assay-based total Ca2+ measurement for the 
anaesthetist, and is readily available on many blood gas 
analysers. 
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Multifunction analysers
A range of handheld and desktop cartridge-based testing 
devices that offer multiple tests are now becoming available. 
Some machines offer full electrolyte panels that rival a 
laboratory assay in terms of accuracy and speed, although 
not usually cost, and some offer tests such as ACT, selected 
hormone levels and D-dimer levels. Several now incorporate 
assays for markers of myocardial necrosis [troponin (I or T) 
and creatine kinase-MB] which facilitate the earlier detection 
of perioperative myocardial infarction, the identification and 
subsequent correct early management of which is now the 
responsibility of the specialist anaesthesiologist. B-type 
natriuretic peptide levels have been increasingly shown to 
be of high importance in perioperative risk stratification of 
patients at risk of myocardial events,6 and several point-of-
care devices now offer this.
Lactate analysis
Blood lactate concentration analysis is now incorporated 
on blood gas analysers and stand-alone devices. Lactate 
measurement is now seen to be essential in directing the 
resuscitation of shocked patients with type A lactic acidosis, 
as well as for the detection of hyperlactataemia and type 
B lactic acidoses from metabolic disorders, mitochondrial 
failure (such as with antiretroviral drug toxicity), and 
disorders of clearance. It also has a role in sports medicine. 
A test that once took a laboratory technician a whole day 
to perform is now available in minutes. Greater use means 
that there is now more debate about the significance of 
lactate levels in various pathologies, which is driving new 
physiological understanding. 
The availability of multiple lactate analysers highlights a 
problem that can be generalised to all point-of-care devices. 
Simultaneous lactate levels measured on two devices are 
rarely identical, and correlation with a laboratory assay is 
sometimes poor.7 Furthermore, fingertip (capillary) lactate 
levels may differ substantially from arterial blood lactate 
levels. Absolute numbers are arguably less important than 
trends in response to therapy for some tests, including 
lactate measurement. It may be acceptable for devices 
in such cases to produce different absolute numbers as 
long as their results all change in the same direction as 
any change in “true” blood levels. (Unfortunately, even this 
does not always happens with current lactate analysers). 
But when absolute levels are set in the literature as decision 
or trigger points for intervention, inaccuracies in point-of-
care device values can have major implications on what 
treatment the patient receives. When using point-of-care 
devices for such “critical threshold level tests”, clinicians 
must pay attention to the quality of the devices they 
use, understand why different analytical techniques may 
produce different results, and develop awareness of issues 
like the limits of agreement between different analytical 
modalities. Clinicians rarely spend much time considering 
such issues. They are often regarded as the specialist realm 
of the chemical or clinical pathologist, but professional 
anaesthesiologists have a responsibility to research the 
workings of the point-of-care devices that they use in daily 
practice to guide their critical clinical decision-making.
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